POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
Latest Information Update: 13 Apr 2026
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Emicizumab (Primary) ; Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms POCUS
Most Recent Events
- 07 Apr 2026 Status changed from recruiting to withdrawn prior to enrolment. ( Due to COVID-19 pandemic, recruitment was temporarily put on hold. We are withdrawing this registration due to a recent amendment to the protocol that includes major changes to data elements. A new registration will be submitted for the new protocol.)
- 03 Mar 2025 Planned End Date changed from 1 Jul 2025 to 1 Jul 2027.
- 03 Mar 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Jul 2027.